My Take: An M&A roadmap to enhance the chances of success


As mergers and acquisitions (M&A) in life sciences continue to make news headlines across the globe, we thought it would be interesting to share insights on this topical issue from Deloitte's U.S. Center for Health Solutions. This “My Take” from the August 19, 2014 Health Care Current written by Homi Kapadia, Vice Chairman, U.S Life Sciences Leader, Deloitte LLP, provides a road map of key questions that might be considered by companies seeking to transform their business through acquisitions, divestitures, or joint ventures. It also poses the question, "What will Congress do?” to pass legislation that makes these kinds of deals less attractive and encourage firms to stay in the U.S.[i]

Posted on 28/08/2014 | 0 Comments

A tale of two systems


Knee replacements are the most common joint replacement operation in Britain, with 90,000 performed each year. A few months ago I had a total knee replacement (TKR) operation in an attempt to relieve the pain and improve mobility of the joint, which had become seriously arthritic following a hockey injury several years ago.

Posted on 20/08/2014 | 0 Comments

Lyme disease - Small bite, big threat


The theme of the World Health Day in April 2014 was vector-borne diseases- ‘Small Bite: Big Threat’. For many people this conjured up thoughts of Malaria, Dengue or West Nile Virus but, few people in the UK are aware that the UK’s most common vector-borne human infection is Lyme disease.[i]

Posted on 14/08/2014 | 0 Comments

Off-label prescribing – a new mechanism for payers to drive down cost


Off-label prescribing is the prescription of a drug for an indication or for an age group, dose or form of administration for which it is not approved. Recently, it has become a thorny topic for the life sciences industry, regulators and healthcare payers, with high profile cases arising in France and Italy.

Posted on 24/07/2014 | 0 Comments

UK Early Access to Medicines Scheme - a new era for patient access


In one of our previous blogs we discussed the US Food and Drug Administration’s (FDA’s) introduction of the ‘breakthrough’ designation concept as a way of improving earlier access to medicines for patients with high unmet medical need. In this blog we’re focussing on the Early Access to Medicines Scheme (EAMS), a similar scheme launched by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in April 2014.

Posted on 18/07/2014 | 0 Comments

Will wearable technology transform healthcare?


Wearable technology is an industry that continues to grow and adapt to meet the ever-changing needs of our world. Many health- and fitness-related technologies have multiple applications and encourage wearers to be more engaged in their own fitness, help modify behavior by reminding wearers to exercise or take medication.

Posted on 2/07/2014 | 0 Comments

Fast-tracking drugs to market – an opportunity for all stakeholders?


One of the key challenges for life science research and development (R&D) is identifying which biochemical pathways and diseases to target. Given the average cost of bringing a new drug to market is now an estimated $1.3 billion dollars as revealed in our 2013 R&D ROI report, it’s clear that R&D leaders are looking to maximise their returns. However, it is also becoming increasingly clear that only those drugs that deliver additional patient benefits will gain approval and funding.

Posted on 18/06/2014 | 0 Comments

How’s your father? Improving the detection and treatment of prostate cancer


Across the UK, prostate cancer kills one man every hour (or 10,636 every year) and is the most common cancer in men. Indeed, 40,000 men are diagnosed with prostate cancer every year and currently there are 255,000 men living with and after the disease.[i] In the UK prostate cancer survival rates are below the European average and quality of care can depend on where you live.

Posted on 12/06/2014 | 0 Comments